Seattle Genetics, Astellas ADC posts strong response in bladder combo study at ESMO

As enfortumab vedotin awaits regulatory action to treat advanced bladder cancer, Seattle Genetics and partner Astellas showed impressive combination data for the antibody-drug conjugate that could quickly move the molecule even earlier in the disease.

In the Phase I EV-103 trial of 45 patients with treatment-naïve locally advanced or metastatic urothelial cancer, 71% of patients treated with a combination of enfortumab vedotin and Keytruda pembrolizumab had a confirmed objective response, including six who had a complete response (13%) and 26 with a partial response (58%). ...